All In Biotech

Drug Trial Radar · NCT07298044

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

A Prospective, Single-arm, Phase 4 Study to Evaluate the Course of Serum Transthyretin (TTR) Level With Acoramidis in Adult Patients With Variant or Wild-type Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Previously Treated With Tafamidis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Sep 17, 2027

Study completion Sep 17, 2027

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM). The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States. Tafamidis is another drug that stabilizes TTR and prevents it from breaking down. In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis. For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark. All participants will continue taking tafamidis during the screening period. In the treatment period of the study, participants will take acoramidis as two tablets twice daily by mouth, for up to 6 months. At the start of this study, the study doctors will review each participant's medical history and check their overall health. The study doctors will perform electrocardiograms (ECG), and measure blood pressure and heart rate. Researchers will also take blood and urine samples from the participants to measure levels of TTr, NT-proBNP, hs-TnT, hs-CRP, RBP4, eGFR, creatinine, cystatin-C, UACR, and TSH at the start of the study, and at various time points thereafter (during the study) to assess heart, kidney and thyroid function. There will be a total of 9 study check-ins. Participants will visit the study site twice: at screening and at the end of treatment period. A study nurse will visit the participant's home 6 times, at the start of treatment, Weeks 1, 2, 3 and 4, then again at 3 months. The final check-in will be done by phone. The study doctors will monitor the health of the participants regularly for any medical problems during follow-up visits. Participants will know the treatment they will receive during the study. Each participant could be in the study for about 8 months.

Conditions

  • Transthyretin Amyloid Cardiomyopathy

Interventions

  • AcoramidisDrug

    356 mg film-coated tablets. The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1424 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in serum TTR level from baseline to month 6 or premature discontinuation of treatmentTime frame: From baseline to month 6 or premature discontinuation of treatment

Locations

26 sites in 5 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3

    Sankt Pölten, Lower Austria, Austria · Withdrawn

  • Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie

    Vienna, State of Vienna, Austria · Recruiting

  • Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie

    Vienna, State of Vienna, Austria · Recruiting

  • Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz

    Vienna, State of Vienna, Austria · Not yet recruiting

  • Medizinische Universität Graz- Klinische Abteilung für Kardiologie

    Vienna, Styria, Austria · Recruiting

  • Krankenhaus St. Josef Braunau | Innere Medizin I

    Braunau am Inn, Upper Austria, Austria · Recruiting

  • VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin

    Feldkirch, Vorarlberg, Austria · Withdrawn

  • Hôpital Erasme/Erasmus Ziekenhuis

    Brussels, Brussels Capital, Belgium · Not yet recruiting

  • AZ St-Jan Brugge-Oostende A.V.

    Bruges, West Flanders, Belgium · Recruiting

  • Sana Klinikum Lichtenberg - Klinik für Innere Medizin II, Schwerpunkt Kardiologie

    Berlin, Germany · Withdrawn

  • Universitätsklinikum Hamburg Eppendorf (UKE)-Universitären Herz- und Gefäßzentrum Hamburg, Klinik für Kardiologie

    Hamburg, Germany · Withdrawn

  • Universitaetsklinikum Ulm | Klinik fuer Innere Medizin II

    Ulm, Baden-Wurttemberg, Germany · Withdrawn

  • KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH

    Darmstadt, Hesse, Germany · Not yet recruiting

  • Universitaetsmedizin Greifswald KöR- Klinik und Poliklinik für Innere Medizin B

    Greifswald, Mecklenburg-Vorpommern, Germany · Withdrawn

  • Universitätsklinikum Bonn - Herzzentrum des Universitätsklinikums Bonn

    Bonn, North Rhine-Westphalia, Germany · Withdrawn

  • Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari

    Naples, Italy · Not yet recruiting

  • Ospedale Vito Fazzi Lecce_Cardiologia e UTIC

    Lecce, Apulia, Italy · Not yet recruiting

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia

    Bologna, Emilia-Romagna, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1

    Bergamo, Lombardy, Italy · Recruiting

  • Centro Cardiologico Monzino S.p.A. - Cardiologia Peri-Operatoria e Imaging Cardiovascolare

    Milan, Lombardy, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo-SC Medicina Generale 2 - Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità

    Pavia, Lombardy, Italy · Not yet recruiting

  • Careggi University Hospital_cardio intensive care unit

    Florence, Tuscany, Italy · Recruiting

  • Fondazione Toscana Gabriele Monasterio_Pisa - Cardiologia e Medicina Cardiovascolare

    Pisa, Tuscany, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Senese - cardiologia

    Siena, Tuscany, Italy · Recruiting

  • Azienda Ospedale-Università di Padova-UOC Cardiologia

    Padova, Veneto, Italy · Recruiting

  • Oslo Universitetssykehus HF, Rikshospitalet

    Oslo, Norway · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.